Review the latest issues of:
- American Society of Clinical Oncology
- ANNUAL MEETING 2010
Our on-site coverage of the annual meeting: Five internationally regarded oncologists give exclusive interviews and expert perspective reports of the highlights of this year’s meeting...
Gastrointestinal Cancers
GI cancer experts Richard M. Goldberg, MD, and Peter C. Enzinger, MD: Clinical investigators share their insight into the best GI sessions and practice-changing trends.
Renal Cell Carcinoma
Andrew J. Armstrong, MD, MSc, and Robert J. Motzer, MD: Learn about the paradigm-shifting advent of targeted therapies; find out what’s down the pike in RCC.
Hematologic Cancers
Samuel M. Silver, MD, PhD: an internationally recognized hematologist shares insight into the future of blood cancer treatment and research, selecting the most relevant content for ASCO 2010.
Plus the hottest American Society of Clinical Oncology news on Breast Cancer, from the CancerNetwork's reporters! 2010 Focus on Breast Cancer
Miami Breast Cancer Conference
In our exclusive on-site coverage of this event, ONCOLOGY has engaged nationally recognized breast cancer specialist Harold J. Burstein, MD, PhD, Associate Professor of Medicine, Harvard Medical School to provide insight on the meeting’s most clinically relevant sessions. Our coverage will also include expert perspectives, abstract/poster reviews, and interviews and podcasts with other leaders in the field. Monitoring Response in CML Treatment Join Dr. Richard Stone of Dana-Farber and CML patient Robert Roy in this new podcast that explores the physician-patient perspective and treatment goals.
|
Top MDs debate the use of Intensity-Modulation Radiation Therapy in the treatment of anal cancer.
IMRT is used with increasing frequency in the treatment of prostate and lung cancers--see what the experts have to say about the pros and cons of this technique.
Flaws in Medicare coding interpretations
Marty Neltner
, September 1, 2010
We work with medical oncologists/hematologists across the country in both the private practice and hospital settings. Based on our experience, I'd like to point out a couple of key flaws in the current Medicare code interpretations.
Doctors as engineers
John Goodman,PhD
, August 31, 2010
There are two fundamentally different ways of thinking about complex social systems: the economic approach and the engineering approach.
NICE rejects Avastin for colorectal cancer
Ron Piana
, August 30, 2010
Despite efforts by the manufacturer to reduce the cost of Avastin, the clinical effectiveness agency for England and Wales says that it will not recommend the drug for the first-line treatment of metastatic colorectal cancer.
Is CMS decision to conduct Provenge NCA based on cost?
Ron Piana
, August 26, 2010
On August 18th during a meeting with “The Pink Sheet Daily” Biotechnology Industry Organization CEO Jim Greenwood said, CMS decision to conduct Provenge NCA could be “Chilling to future innovation.”
Recent comments from your peers: "An 82-year-old patient with Alzheimer's and breast cancer who has undergone radiation treatment that has minimized the tumor has to be given the choice between a mastectomy and the tumor coming back. Co-morbidities include diabetes and heart problems. Obsessive behavior is increasing with Alzheimer's, including lack of perspective. What is best?"
Add Your Response "While the reduction in mortality rates [from PSA screening] is significant, I would be interested to know what effect earlier detection had on side effects such as incontinence and impotence. Is such data available?"
Add Your Response "Has there been any research on the number of patients with newly diagnosed breast cancer having undergone MRI on which a contralateral malignancy was detected? If that malignancy were mammographically occult, would it not be advantageous to find it at an earlier stage before treating the patient?"
Add Your Response
|
CancerNetwork.com offers a variety of Continuing Medical Education (CME) programs based on ONCOLOGY review articles, supplements to ONCOLOGY and Oncology News International, textbooks, roundtable discussions, e-learning programs and webcasts.  These interactive CME activities are offered to physicians and other healthcare professionals without charge by CME.
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Click here to see a list of CME activities.
Integrating Genetics and Genomics Into Oncology Nursing
March 1, 2010
By Dale Halsey Lea, MPH, RN, CGC, FAAN
Health Educator, National Human Genome Research Institute
This activity is based on articles and reports in ONCOLOGY Nurse Edition. It is developed from an identified educational need for information about practical management issues in medical, surgical, and radiation oncology. This activity has been developed and approved under the direction of CME LLC.
CME, 1.0 Credits
Hosted on cmellc.com
CME LLC's Highlights in Breast Cancer Treatment From the ASCO® 2009 Annual Meeting
Update 1: Concept of Maintenance
Chemotherapy in NSCLC
Update 2: MSI - To Test or Not To Test
Update 3: MSI - The Role of Cetuximab in NSCLC
(Lancet-flex Study)
Update 4: New Studies in GI Cancer
Update 5: Patient Selection for Adjuvant Therapy
Tumor Board Events On-Demand
In Streaming Video
Learn from thought leaders through interactive webcast discussions, designed to help you navigate treatment challenges in oncology.
New Perspectives in Metastatic Breast Cancer 2009
An Online Tumor Board Event
Hosted by:
Program Chair: Andrew D. Seidman, MD,
Professor of Medicine, Weill Medical College of Cornell University Attending Physician, Memorial Sloan-Kettering Cancer Center New York, NY
Renal Cell Carcinoma
An On-Demand Tumor Board Event
Hosted by:
Program Chair: Ronald M. Bukowski, MD,
Emeritus Staff, CCF Taussing Cancer Center Proffessor of Medicine, CCF Lerner College of Medicine of CWRU, Case Western
Chronic Myelogenous Leukemia
An On-Demand Tumor Board Event
Hosted by:
Program Chair: Charles A. Schiffer, MD,
Director, Multidisciplinary Leukemia Lymphoma Medical Oncology, Wayne State University School of Medicine, Detroit
|
|
